Back

Sodium glucose cotransporter 2 inhibitors for all HFrEF patients: can we afford it? A cost-effectiveness analysis of dapagliflozin

European Journal of Preventive Cardiology

22 July 2020
Organised by: Logo
Read full article
ESC Journals

Contributors

Marcus Dörr
Marcus Dörr

Author

ESC 365 is supported by

novartis Explore sponsored resources